ESMO 2017 | The delivery of niraparib and rucaparib as ovarian cancer treatment options
Currently, the only labelled PARP inhibitor for use in treating BRCA-mutated ovarian cancer in Europe is olaparib. Mansoor Mirza, MD, from the Copenhagen University Hospital, Copenhagen, Denmark explains his hopes that niraparib and rucaparib, two PARP inhibitors recently assessed in clinical trials, will also become available as a treatment option and discusses the socioeconomic factors associated with the introduction of these agents. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up